Genscript Biotech Corporation reported earnings results for the full year ended December 31, 2021. For the full year, the company reported sales was USD 511.06 million compared to USD 390.85 million a year ago. Net loss was USD 347.87 million compared to USD 204.95 million a year ago.

Basic loss per share from continuing operations was USD 0.1713 compared to USD 0.1078 a year ago. Diluted loss per share from continuing operations was USD 0.1713 compared to USD 0.1078 a year ago.